Inhibition of RANK/RANKL signal transduction pathway: A promising approach for osteoporosis treatment

Medical Hypotheses

Volumn 71, Issue 2, 2008, Pages 256-258

  Bai, Yu Di ^a   Yang, Fu Sheng ^a   Xuan, Kun ^a   Bai, Yu Xiang ^a   Wu, Bu Ling ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ARTICLE; BONE METASTASIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL TRIAL; HUMAN; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BONE RESORPTION; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HUMANS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; OSTEOCLASTS; OSTEOPOROSIS; PROTEIN BINDING; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 45649084334     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.03.021     Document Type: Article

References (21)

1. Hughes A.E., Ralston S.H., Marken J., et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24 1 (2000) 45-48
2. Chrischilles E.A., Butler C.D., Davis C.S., and Wallace R.B. A model of lifetime osteoporosis impact. Arch Intern Med 151 10 (1991) 2026-2032
3. Vega D., Maalouf N.M., and Sakhaee K. Clinical review: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92 12 (2007) 4514-4521
4. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 7 (1998) 3597-3602
5. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 6717 (1999) 315-323
6. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 7 (1999) 3540-3545
7. Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life 57 (2005) 389-395
8. Katagiri T., and Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8 3 (2002) 147-159
9. Kearns A.E., Khosla S., and Kostenuik P. RANKL and OPG regulation of bone remodeling in health and disease. Endocr Rev 5 (2007) [Epub ahead of print]
10. Schwarz E.M., and Ritchlin C.T. Clinical development of anti-RANKL therapy. Arthritis Res Ther 9 Suppl 1 (2007) S7
11. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., and Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15 1 (2000) 2-12
12. Blair J.M., Zheng Y., and Dunstan C.R. RANK Ligand. Int J Biochem Cell Biol 39 6 (2007) 1077-1081
13. Yasuda H., Shima N., Nakagawa N., et al. Identification of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
14. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., and Kanno T. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247 3 (1998) 610-615
15. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., and Capparelli C. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 9 (1998) 1260-1268
16. Kostenuik P.J. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5 (2005) 618-625
17. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21 (2000) 115-137
18. Zhang Y.H., Heulsmann A., Tondravi M.M., Mukherjee A., and Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276 1 (2001) 563-568
19. Azuma Y., Kaji K., Katogi R., Takeshita S., and Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275 7 (2000) 4858-4864
20. Gori F., Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Khosla S., and Riggs B.L. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141 12 (2000) 4768-4776
21. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., and Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 9 (1999) 4367-4370